報價延遲最少15分鐘:2025/05/30 12:58 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.2528 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.63/-0.63
|
|
企業價值
12.57M
|
| 資產負債 |
|
每股賬面淨值
0.17
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/05/30 12:58 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer. |